title: CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors.
abstract: Genetic variation in the cytochrome P450 2C19 (CYP2C19) gene has been documented gradually as the determinant conversion and variability in the antiplatelet effect of clopidogrel. The aims of this study were to determine the prevalence of clinically relevant allele variants (CYP2C19*2, CYP2C19*3, and CYP2C19*17) in a Thai study population, and finally determine whether the allele distributes and predicts metabolic phenotypes in clopidogrel treated patients. A total of 1,051 Thai patients participated in this study. Genotypes for CYP2C19 polymorphisms were detected by the microarray-based technique. Furthermore, results of genotyping and platelet aggregation in 96 cardiovascular disease patients on 75 mg clopidogrel maintenance daily dose therapy also were analyzed. Among 1,051 samples, the allele frequencies of CYP2C19 *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *1/*17 were found in 428 (40.72%), 369 (35.10%), 72 (6.85%), 77 (7.32%), 59 (5.61%), and 45 (4.30%) of the patients, respectively. Homozygous CYP2C19 *3/*3 was found in one patient (0.10%). Therefore, 40.72% of the patients were predicted as extensive metabolizers, 41.95% as intermediate metabolizers, 13.03% as poor metabolizers, and 4.30% as ultra-rapid metabolizers. Among 96 patients, the frequency of poor metabolizers was significantly higher in the clopidogrel non-responder group than in the responder group (36.0% and 15.5%, respectively, P = 0.03). CYP2C19*1/*17 was observed in responders (n = 2; 2.8%). As a result, CYP2C19 variants were associated with clopidogrel non-responders. However, there is a need for further elucidation of the clinical importance and use of this finding to make firm and cost-effective recommendations for drug treatment in the future.
authors.affiliation: Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: Chonlaphat
authors.initials: C
authors.lastname: Sukasem
authors.forename: Ramaimon
authors.initials: R
authors.lastname: Tunthong
authors.forename: Montri
authors.initials: M
authors.lastname: Chamnanphon
authors.forename: Siwalee
authors.initials: S
authors.lastname: Santon
authors.forename: Thawinee
authors.initials: T
authors.lastname: Jantararoungtong
authors.forename: Napatrupron
authors.initials: N
authors.lastname: Koomdee
authors.forename: Santirhat
authors.initials: S
authors.lastname: Prommas
authors.forename: Apichaya
authors.initials: A
authors.lastname: Puangpetch
authors.forename: Prin
authors.initials: P
authors.lastname: Vathesatogkit
keywords: CYP2C19 polymorphisms; Thai population; clopidogrel; non-responders; responders
references.citation: N Engl J Med. 2009 Jan 22;360(4):411-3
references.pmid: 19164193
references.citation: J Clin Pharmacol. 2008 Apr;48(4):475-84
references.pmid: 18303127
references.citation: Blood. 2006 Oct 1;108(7):2244-7
references.pmid: 16772608
references.citation: Pharmacology. 2007;79(4):203-6
references.pmid: 17374963
references.citation: Clin Pharmacol Ther. 1999 Aug;66(2):185-92
references.pmid: 10460072
references.citation: Clin Pharmacol Ther. 1996 Dec;60(6):661-6
references.pmid: 8988068
references.citation: J Thromb Haemost. 2007 Dec;5(12):2429-36
references.pmid: 17900275
references.citation: Clin Pharmacol Ther. 2011 Aug;90(2):328-32
references.pmid: 21716271
references.citation: Clin Pharmacol Ther. 2006 Nov;80(5):486-501
references.pmid: 17112805
references.citation: Clin Pharmacokinet. 2002;41(12):913-58
references.pmid: 12222994
references.citation: J Pharmacol Exp Ther. 1999 Aug;290(2):635-40
references.pmid: 10411572
references.citation: Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1895-900
references.pmid: 16645157
references.citation: Clin Pharmacol Ther. 1985 Oct;38(4):402-8
references.pmid: 4042523
references.citation: Clin Pharmacol Ther. 2006 Jan;79(1):103-13
references.pmid: 16413245
references.citation: Br J Clin Pharmacol. 2003 Dec;56(6):653-7
references.pmid: 14616425
references.citation: Thromb Haemost. 2003 May;89(5):783-7
references.pmid: 12719773
references.citation: N Engl J Med. 2009 Jan 22;360(4):363-75
references.pmid: 19106083
references.citation: J Biol Chem. 1994 Jun 3;269(22):15419-22
references.pmid: 8195181
references.citation: Br J Clin Pharmacol. 2004 Sep;58(3):332-5
references.pmid: 15327595
references.citation: Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1-2):102-5
references.pmid: 17201743
references.citation: Lancet. 2009 Jan 24;373(9660):309-17
references.pmid: 19108880
references.citation: Clin Pharmacol Ther. 1998 Apr;63(4):422-7
references.pmid: 9585796
references.citation: Clin Pharmacol Ther. 1998 Oct;64(4):391-401
references.pmid: 9797796
references.citation: Br J Clin Pharmacol. 2001 Oct;52(4):349-55
references.pmid: 11678778
references.citation: J Am Coll Cardiol. 2008 May 20;51(20):1925-34
references.pmid: 18482659
references.citation: Pharmacogenomics. 2008 Sep;9(9):1251-9
references.pmid: 18781853
references.citation: Pharmacogenet Genomics. 2007 Dec;17(12):1057-64
references.pmid: 18004210
references.citation: Pharmacogenetics. 1997 Feb;7(1):59-64
references.pmid: 9110363
references.citation: N Engl J Med. 2009 May 21;360(21):2250-1
references.pmid: 19469033
references.citation: Eur Heart J. 2009 Apr;30(8):916-22
references.pmid: 19193675
references.citation: J Pharmacol Exp Ther. 1997 Apr;281(1):604-9
references.pmid: 9103550
references.citation: Circulation. 2003 Aug 26;108(8):989-95
references.pmid: 12912815
references.citation: Blood Coagul Fibrinolysis. 2004 Jan;15(1):89-93
references.pmid: 15166949
references.citation: Can J Clin Pharmacol. 2009 Winter;16(1):e156-62
references.pmid: 19193970
references.citation: Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95
references.pmid: 15499174
references.citation: Eur J Clin Pharmacol. 2002 Apr;58(1):15-8
references.pmid: 11956668
references.citation: Trends Pharmacol Sci. 2001 Jun;22(6):298-305
references.pmid: 11395158
references.citation: Drug Metab Pharmacokinet. 2006 Aug;21(4):286-90
references.pmid: 16946555